DiaSorin S.p.A. (OTCMKTS:DSRLF – Get Free Report) saw an uptick in trading volume on Wednesday . Approximately 1,000 shares traded hands during mid-day trading, an increase of 179% from the previous session’s volume of 359 shares.The stock last traded at $81.00 and had previously closed at $80.00.
Analyst Ratings Changes
Several research analysts recently weighed in on DSRLF shares. UBS Group cut DiaSorin from a “buy” rating to a “neutral” rating in a research report on Thursday, April 9th. BNP Paribas Exane cut shares of DiaSorin from a “neutral” rating to an “underperform” rating in a research note on Tuesday, July 7th. Zacks Research raised shares of DiaSorin to a “hold” rating in a report on Tuesday, May 12th. Piper Sandler started coverage on shares of DiaSorin in a research note on Thursday, June 11th. They issued a “neutral” rating for the company. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of DiaSorin from a “hold” rating to a “sell” rating in a report on Wednesday, June 17th. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, DiaSorin presently has an average rating of “Hold”.
Check Out Our Latest Research Report on DSRLF
DiaSorin Price Performance
DiaSorin Company Profile
DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.
At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.
Featured Stories
- Five stocks we like better than DiaSorin
- Broadcom’s $200 Billion Samsung Deal Shows How Costly the AI Memory Race Has Become
- 3 Refiners Benefiting From Oil Volatility and Tight Fuel Supply
- Carrier Earnings Could Send the Stock to a New All-Time High
- 3 Unique AI Software Plays With Strong Analyst Support
Receive News & Ratings for DiaSorin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaSorin and related companies with MarketBeat.com's FREE daily email newsletter.
